Specific binding of melatonin to purified cell nuclei from mammary gland of swiss mice: Day-night variations and effect of continuous light

Journal of Pineal Research

Volumn 34, Issue 4, 2003, Pages 297-301

  Coto Montes, Ana ^a   Tomás Zapico, Cristina ^a   Escames, Germaine ^b   León, Josefa ^b   Rodríguez Colunga, María Josefa ^a   Tolivia, Delio ^a   Acuña Castroviejo, Darío ^b,c  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Mammary gland; Melatonin; Mouse; Nuclear melatonin receptor; Photoperiod; Pineal gland

Indexed keywords

MELATONIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL NUCLEUS; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG BINDING; IC 50; MAMMARY GLAND; MOUSE; MOUSE STRAIN; NONHUMAN; PHOTOPERIODICITY; REGULATORY MECHANISM;

EID: 0037405563     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-079X.2003.00049.x     Document Type: Article

References (44)

1. RECIO J, CARDINALI DP, SANCHEZ-BARCELÓ EJ. 2-[125I] iodomelatonin binding sites in murine mammary tissue. Biol Signals 1994; 3:85-90.
2. MEDIAVILLA MD, SAN MARTIN M, BONANNI REY RA et al. Melatonin actions in mouse mammary glands. In: Melatonin and Pineal Gland. From Basic Science to Clinical Applications. Touitou Y, Arendt J, Pevet P, eds., Elsevier, Amsterdam, 1993; pp. 261-264.
3. CONTI A, MAESTRONI GJM. HPLC validation of a circadian melatonin rhythm in the pineal gland of inbred mice. J Pineal Res 1996; 20:138-144.
4. KHALDY H, LEÓN J, ESCAMES G et al. Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and a melatoni treatment. Neuroendocrinology 2002; 75:201-208.
5. REITER RJ, TAN DX, QI W et al. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000; 9:160-171.
6. REITER RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12:51-180.
7. REITER RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49:654-664.
8. BLASK DE. Melatonin in oncology. In: Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications. Yu H-S, Reiter RJ, eds., CRC Press, Boca Raton, 1993; pp. 447-475.
9. BLASK DE. An overview of the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In: The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Bartsch C, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. Springer-Verlag, Berlin, 2001; pp. 309-335.
10. COS S, SANCHEZ-BARCELO EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21:133-170.
11. COS S, SANCHEZ-BARCELO EJ. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 2000; 15:637-647.
12. COS S, MEDIAVILLA MD, FERNÁNDEZ R et al. Does melatonin induce apoptosis in MCF-7 human breast cancer cell in vitro? J Pineal Res 2002; 32:90-96.
13. COS S, SANCHEZ-BARCELO EJ. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett 1994; 85:105-109.
14. BARTSCH H, BARTSCH C, DEERBERG F et al. Seasonal rhythms of 6-sulphatoxymelatonin (aMT6s) excretion in female rats are abolished by growth of malignant tumors. J Pineal Res 2001; 31:57-61.
15. TAN DX, REITER RJ, MANCHESTER LC et al. Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-197.
16. POEGGELER B, THUERMANN S, DOSE A et al. Melatonin's unique radical scavenging properties - roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 2002; 33:20-30.
17. 2+. J Pineal Res 2001; 31:314-319.
18. ACUÑA-CASTROVIEJO D, REITER RJ, MENENDEZ-PELAEZ A et al. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res 1994; 16:100-112.
19. BLUM M, MCEWN BS, ROBERTS JL. Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987; 262:817-821.
20. BRADFORD MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
21. RECIO J, MEDIAVILLA MD, CARDINALI DP et al. Pharmacological profile and diurnal rhythmicity of 2-[125I]-iodomelatonin binding sites in murine mammary tissue. J Pineal Res 1994; 16:10-17.
22. MESSNER M, HARDELAND R, RODENBECK A et al. Tissue retention and subcellular distribution of continuously infused melatonin in rats under near physiological conditions. J Pineal Res 1998; 25:251-259.
23. TAN DX, MANCHESTER LC, REITER RJ et al. High physiological levels ofmelatonin in the bile of mammals. Life Sci 1999; 65:2523-2529.
24. SKINNER DC, MALPAUX B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculation through the choroid plexus. Endocrinology 1999; 140:4399-4405.
25. ZISAPEL N, NIR I, MOSHE L. Circadian variations in melatonin-binding sites in discrete areas of the male rat brain. FEBS Lett 1988; 232:172-176.
26. LAITINEN JT, CASTREN E, VAKKURI O et al. Diurnal rhythm of melatonin binding in the rat suprachiasmatic nucleus. Endocrinology 1989; 124:1585-1587.
27. VANECEK J, KOSAR JE, VORLIJEK J. Daily changes in melatonin binding sites and the effect of castration. Mol Cel Endocrinol 1990; 73:165-170.
28. 125I]melatonin-binding sites in the bursa of Fabricius of birds: binding characteristics, subcellular distribution, diurnal variations and age studies. J Endocrinol 1993; 138: 51-57.
29. 125I]iodomelatonin binding sites in the guinea pig spleen. Neurosci Lett 1992; 146:41-44.
30. RAFII-EL-IDRISSI M, CALVO JR, GIORDANO M et al. Specific binding of 2-[125I]iodomelatonin by rat spleen crude membranes: day-night variations and effect of pinealectomy and continuous light exposure. J Pineal Res 1996; 20:33-38.
31. REITER RJ, PETTERBOURG LJ, TRAKULRUNGSI C et al. Surgical removal of the olfatory bulbs increases sensitivity of the reproductive system of female rats to the inhibitory effects of late afternoon metabolism injection. J Exp Zool 1980; 212:47-52.
32. SANCHEZ-BARCELO EJ, MEDIAVILLA MD, TUCKER HA. Influence of melatonin on mammary gland growth: in vivo and in vitro studies. Proc Soc Exp Biol Med 1990; 194:103-107.
33. SUBRAMANIAN A, KOTHARI L. Melatonin, a suppressor of spontaneous murine mammary tumors. J Pineal Res 1991; 10:136-140.
34. MEDIAVILLA MD, SAN MARTIN M, SANCHEZ-BARCELO EJ. Melatonin inhibits mammary gland development in female mice. J Pineal Res 1992; 13:13-19.
35. MEDIAVILLA MD, GUEZMEZ A, RAMOS S et al. Effects of melatonin on mammary gland lesions in trangenic mice overexpressing N-ras proto-oneogene. J Pineal Res 1997; 22:86-94.
36. BLASK DE, SAUER LA, DAUCHY RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2:113-132.
37. RAM PT, YUAN L, DAI J. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone melatonin. J Pineal Res 2000; 28:210-218.
38. COS S, FERNANDEZ R. Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells. J Pineal Res 2000; 29:166-171.
39. PANZER A, VILJOEN M. The validity of melatonin as an oncostatic agent. J Pineal Res 1997; 22:184-202.
40. LISSONI P, ROVELLI F, MALUGANI F et al. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett 2001; 22:45-47.
41. KIEFER T, RAM PT, YUAN L et al. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002; 71:37-45.
42. WINCZYK K, PAWLIKOWSKI M, KARASEK M. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res 2001; 31:179-182.
43. ALLEGRA M, REITER RJ, TAN DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
44. TAN DX, MANCHESTER LC, HARDELAND R et al. Melatonin: a hormone, a tissue factor, an autacoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34:75-78.